Question explored with the scientific record
Conversation so far
- 1 Do statins have good studies behind them?
- 2 Do statins increase serious side effects like diabetes or muscle injury?
Answered on this page ↓
Do statins increase serious side effects like diabetes or muscle injury?
The short version: statins clearly increase the risk of new-onset diabetes and muscle injury, but the absolute risk of severe muscle injury is low for most people.
Yes, statins increase the risk of new-onset diabetes. A meta-analysis of 11 studies covering 236,864 people found statin use raised the odds of new diabetes by about 61% (fixed-effects OR 1.61, 95% CI 1.55–1.68) [3]. The risk is dose-dependent: high-intensity statins like rosuvastatin 20 mg produced an 8.3% diabetes rate versus 5.8% for moderate-intensity therapy in one 2023 Korean cohort [1, 2]. A 2024 nationwide study of heart attack patients found the same pattern: atorvastatin 80 mg gave a 7.7% diabetes rate, while 10 mg gave 5.7% [1]. The JUPITER trial, funded by the manufacturer, reported a 0.6% absolute increase in diabetes over two years on rosuvastatin [4, 5]. The mechanism is not a mystery: statins impair pancreatic beta-cell function, reduce insulin signaling, and increase hepatic glucose production [5].
Muscle injury is also real. In randomized trials, myalgia (muscle pain without enzyme elevation) occurred in 1.5% to 5% of patients [8]. The PRIMO observational study of 7,942 patients found muscle symptoms in 10.5% [9]. Severe rhabdomyolysis is rarer: about 0.44 per 10,000 statin-treated patients in one large database study [9], though the withdrawn drug cerivastatin had a 12-fold higher risk [9]. A 2006 meta-analysis of 35 trials found no statistically significant increase in rhabdomyolysis for FDA-approved statins, but the confidence intervals were wide [7]. The risk is higher with high doses, in older patients, in those with kidney disease, and with interacting drugs like gemfibrozil [6, 8, 10].
| Outcome | Statin group risk | Comparison | Source |
|---|---|---|---|
| New-onset diabetes (meta-analysis) | OR 1.61 (fixed) | No statin | [3] |
| New-onset diabetes (high vs moderate intensity) | 8.3% vs 5.8% | Moderate intensity | [2] |
| Myalgia (RCTs) | 1.5–5% | Placebo | [8] |
| Myalgia (observational, PRIMO) | 10.5% | — | [9] |
| Rhabdomyolysis (database) | 0.44 per 10,000 | — | [9] |
The evidence is mostly from manufacturer-funded trials and observational studies, not independent long-term safety trials. The absolute risk of severe muscle injury is low, but the diabetes risk is consistent and dose-dependent. For a person deciding whether to start a statin, the question is whether the cardiovascular benefit outweighs these real harms, and that depends on their individual risk profile, not a blanket "safe and effective" claim.
My call: statins increase the risk of new diabetes and muscle symptoms, with severe injury being rare. Confidence: high for the diabetes link, moderate for the muscle risk estimates, because the trials underreport symptoms and the observational data is more informative.
Sources used 10
-
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
New onset diabetes mellitus and cardiovascular outcomes according to statin intensity in patients after drug-eluting stent implantation in Asian patients
High-intensity statin therapy was associated with a higher incidence of new onset diabetes mellitus but not with better cardiovascular outcomes in Korean patients undergoing percutaneous coronary intervention.
DOI: 10.1038/s41598-023-42277-w -
Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis
A meta-analysis of 11 studies (236,864 subjects) found statin use was associated with a small but statistically significant increased risk of new-onset diabetes mellitus (fixed-effects OR 1.61, 95% CI 1.55-1.68; p < 0.001).
DOI: 10.1159/000485196 -
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus
This study investigates the association of lipoprotein subclasses and a novel lipoprotein insulin resistance (LPIR) score with the incidence of type 2 diabetes mellitus (T2DM) among individuals randomized to receive either rosuvastatin or placebo in the JUPITER trial, revealing …
DOI: 10.1001/jamacardio.2016.0096 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Risk factors for statin‐associated rhabdomyolysis
This study identifies and characterizes risk factors for rhabdomyolysis in patients prescribed statin monotherapy or statin plus fibrate therapy, finding that older age significantly increases the risk, along with potential contributions from high statin dosage and renal disease.
DOI: 10.1002/pds.1287 -
Risks Associated With Statin Therapy
This is a systematic overview and meta-analysis of randomized statin trials assessing adverse events; it finds a small increased risk of transaminase elevations with statins (unchanged risks for myalgias, CK elevations, rhabdomyolysis, or overall discontinuations) and notes ceri…
DOI: 10.1161/CIRCULATIONAHA.106.624890 -
Narrative Review: Statin-Related Myopathy
This narrative review synthesizes current knowledge on statin-related myopathy, detailing definitions, mechanisms, epidemiology, clinical features, risk factors, management strategies, and emerging pharmacogenetic and adjunctive treatment data.
DOI: 10.7326/0003-4819-150-12-200906160-00009 -
Statin-associated myopathy: a general overview
This narrative review summarizes statin-associated myopathy, its clinical spectrum, proposed mechanisms, risk factors, and management, citing prior observational and interventional studies.
DOI: 10.18621/eurj.416772 -
The safety of statins in clinical practice
A comprehensive 2007 Lancet review assessing the safety of statins in clinical practice, detailing muscle and liver adverse effects, dose-related risks, drug interactions, and safety across diverse patient groups, and concluding that statins are generally well tolerated with cau…
DOI: 10.1016/S0140-6736(07)60716-8